Allogeneic HLA-matched donor dendritic cells loaded with patient leukemic blasts preferentially induce CD4-positive leukemia-reactive donor lymphocytes

Acta Haematologica

Volumn 117, Issue 4, 2007, Pages 226-235

  Thomas Kaskel, Anna Katharina ^a   Alves Portugal, Tatiana Gil ^a   Herchenbach, Dieter ^a   Houet, Leonora ^a   Veelken, Hendrik ^a   Finke, Jürgen ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Acute myeloid leukemia; Donor lymphocyte infusion; Leukemia specific donor lymphocytes

Indexed keywords

GAMMA INTERFERON;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CELL FRACTIONATION; CELL LINE; CELL MATURATION; CELL SPECIFICITY; CELL STIMULATION; CONTROLLED STUDY; DENDRITIC CELL; DONOR LYMPHOCYTE INFUSION; ENZYME LINKED IMMUNOSPOT ASSAY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL LINE, TUMOR; DENDRITIC CELLS; FEMALE; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOPHENOTYPING; INTERFERON TYPE II; LEUKEMIA; LYMPHOCYTES; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 34249037102     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000099547     Document Type: Article

References (36)

1. Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM: Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000;6:1018-1023.
2. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermueller J, de Witte T, Holler E, Ansari H; European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-2050.
3. MacKinnon S: Who may benefit from donor leucocyte infusions after allogeneic stem cell transplantation? Br J Haematol 2000;110:12-17.
4. Falkenburg JH, Wafelman AR, Joosten P, Smit WM, van Bergen CA, Bongaerts R, Lurvink E, van der Hoorn M, Kluck P, Landegent JE, Kluin-Nelemans HC, Fibbe WE, Willemze R: Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood 1999;94:1201-1208.
5. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J, Gratwohl A, Vogelsang GB, van Houwelingen HC, van Rood JJ: Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281-285.
6. Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E: Tetrameric HLA class I-minor histocompatibility antigen peptide complexes demonstrate minor histocompatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-host disease. Nat Med 1999;5:839-842.
7. Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C: Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med 2001;7:789-794.
8. Warren EH, Greenberg PD, Riddell SR: Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 1998;91:2197-2207.
9. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E: Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood 1999;93:2336-2341.
10. + minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 1999;96:8639-8644.
11. Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, Rojas J, Bourdon A, Bonner PL, Wang L, Christmas SE, Travers PJ, Creaser CS, Rees RC, Madrigal JA: Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001;98:2887-2893.
12. Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S, Nagorsen D, Keilholz U: CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002;100:2132-2137.
13. Oka Y, Elisseeva OA, Tsuboi A, Ogawa H, Tamaki H, Li H, Oji Y, Kim EH, Soma T, Asada M, Ueda K, Maruya E, Saji H, Kishimoto T, Udaka K, Sugiyama H: Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product. Immunogenetics 2000;51:99-107.
14. + progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000;95:2198-2203.
15. Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N, Fukushima P, Barrett AJ: Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996;88:2450-2457.
16. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG, Rieber EP: Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000;60:4845-4849.
17. Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, Grunebach F, Brossart P: Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003;102:571-576.
18. van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, Olive D, Boon T, Coulie PG: PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998;102:1376-1379.
19. Delluc S, Tourneur L, Michallet AS, Boix C, Varet B, Fradelizi D, Guillet JG, Buzyn A: Autologous peptides eluted from acute myeloid leukemia cells can be used to generate specific antileukemic CD4 helper and CD8 cytotoxic T lymphocyte responses in vitro. Haematologica 2005;90:1050-1062.
20. Montagna D, Maccario R, Locatelli F, Rosti V, Yang Y, Farness P, Moretta A, Comoli P, Montini E, Vitiello A: Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood 2001;98:3359-3366.
21. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, Scott B: Tumor-specific CD4+ T cells have a major 'post-licensing' role in CTL mediated anti-tumor immunity. J Immunol 2000;165:6047-6055.
22. Pardoll DM, Topalian SL: The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588-594.
23. Maus MV, Thomas AK, Leonard DG, Allman D, Addya K, Schlienger K, Riley JL, June CH: Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat Biotechnol 2002;20:143-148.
24. Thomas AK, Maus MV, Shalaby WS, June CH, Riley JL: A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol 2002;105:259-272.
25. Kalergis AM, Ravetch JV: Inducing tumor immunity through the selective engagement of activating Fcγ receptors on dendritic cells. J Exp Med 2002;195:1653-1659.
26. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV: Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002;195:125-133.
27. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P: Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res 2004;64:5934-5937.
28. + early progenitor cells. Blood 1997;90:1083-1090.
29. Mutis T, Schrama E, Melief CJ, Goulmy E: CD80-transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens. Blood 1998;92:1677-1684.
30. + T cells with a regulatory phenotype and function. Eur J Immunol 2005;35:2896-2908.
31. Murai M, Yoneyama H, Ezaki T, Suematsu M, Terashima Y, Harada A, Hamada H, Asakura H, Ishikawa H, Matsushima K: Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat Immunol 2003;4:154-160.
32. Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR, Ferrara JL: Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002;8:575-581.
33. Levine BL, Bernstein WB, Connors M, Craighead N, Lindsten T, Thompson CB, June CH: Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells. J Immunol 1997;159:5921-5930.
34. Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, Thompson CB: CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995;3:87-98.
35. Weng NP, Levine BL, June CH, Hodes RJ: Regulated expression of telomerase activity in human T lymphocyte development and activation. J Exp Med 1996;183:2471-2479.
36. Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, Stevens R, Hazen A, Blaese RM, Chen CC, Leitman SF, Palensky J, Wittes J, Davey RT Jr, Falloon J, Polis MA, Kovacs JA, Broad DF, Levine BL, Roberts MR, Masur H, Lane HC: Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood 2000;96:467-474.